BR112022010875A2 - Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido - Google Patents

Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido

Info

Publication number
BR112022010875A2
BR112022010875A2 BR112022010875A BR112022010875A BR112022010875A2 BR 112022010875 A2 BR112022010875 A2 BR 112022010875A2 BR 112022010875 A BR112022010875 A BR 112022010875A BR 112022010875 A BR112022010875 A BR 112022010875A BR 112022010875 A2 BR112022010875 A2 BR 112022010875A2
Authority
BR
Brazil
Prior art keywords
tablet
film
coated
swallowable
prepare
Prior art date
Application number
BR112022010875A
Other languages
English (en)
Inventor
NOGUEIRAS NIETO Luis
Alvarez Fernandez Lisardo
Kumar Rohit
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of BR112022010875A2 publication Critical patent/BR112022010875A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPRIMIDO DEGLUTÍVEL REVESTIDO POR PELÍCULA, PROCESSO PARA PREPARAR O COMPRIMIDO, E, USO DE UM COMPRIMIDO. A presente invenção se refere a um comprimido deglutível revestido por película que compreende eltrombopague bis(monoetanolamina) e excipientes farmaceuticamente aceitáveis que compreendem silicato de cálcio como diluente. A invenção se refere adicionalmente ao uso do dito comprimido como um medicamento, particularmente no tratamento de trombocitopenia imune (ITP), trombocitopenia em pacientes com vírus da hepatite C crônica (HCV) e anemia aplástica grave (SAA).
BR112022010875A 2019-12-06 2020-12-04 Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido BR112022010875A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214295 2019-12-06
PCT/EP2020/084723 WO2021110959A1 (en) 2019-12-06 2020-12-04 Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)

Publications (1)

Publication Number Publication Date
BR112022010875A2 true BR112022010875A2 (pt) 2022-08-23

Family

ID=68835041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010875A BR112022010875A2 (pt) 2019-12-06 2020-12-04 Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido

Country Status (6)

Country Link
US (1) US20230022228A1 (pt)
EP (1) EP4069204A1 (pt)
AU (1) AU2020397233A1 (pt)
BR (1) BR112022010875A2 (pt)
CA (1) CA3160779A1 (pt)
WO (1) WO2021110959A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116637091B (zh) * 2023-07-24 2023-10-03 山东则正医药技术有限公司 一种艾曲波帕乙醇胺口溶膜及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2015029074A2 (en) 2013-09-02 2015-03-05 Hetero Research Foundation Compositions of eltrombopag
CN107693515B (zh) 2016-08-08 2022-04-29 广东东阳光药业有限公司 含碱化剂和艾曲泊帕的药物组合物及其用途
WO2018078644A1 (en) * 2016-10-24 2018-05-03 Hetero Labs Limited Orally disintegrating tablets of eltrombopag
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder

Also Published As

Publication number Publication date
AU2020397233A1 (en) 2022-06-30
EP4069204A1 (en) 2022-10-12
CA3160779A1 (en) 2021-06-10
WO2021110959A1 (en) 2021-06-10
US20230022228A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
BR112018071585A2 (pt) formulações de um inibidor de lsd1
PH12016501762A1 (en) Hepatitis b core protein allosteric modulators
CO2021011295A2 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
BR112022010875A2 (pt) Comprimido deglutível revestido por película, processo para preparar o comprimido, e, uso de um comprimido
BR112017005828A2 (pt) métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica.
PH12018502735A1 (en) Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof
BR112014015582A8 (pt) compostos antivirais
MX2020008360A (es) Forma cristalina de bictegravir sodico.
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
BR112022009421A2 (pt) Regimes de dosagem para vacinas
MX2021013594A (es) Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
BR102017022849A8 (pt) Usos terapêuticos de agentes antivirais de ação direta para tratar ou prevenir uma infecção com genótipo 1 a 6 do vírus da hepatite c
EA033921B9 (ru) Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа
CL2022003712A1 (es) Formulaciones
BR112016020895A2 (pt) moduladores alostéricos da proteína do núcleo da hepatite b
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]